Sanofi has announced that its half-year financial report for the period ending June 30, 2025 is now available to the public. The company has filed the report with both the French market regulator Autorité des marchés financiers (AMF) and the U.S. Securities and Exchange Commission (SEC) under form 6-K.
The financial report can be accessed through Sanofi’s corporate website at www.sanofi.com, specifically on the “Investors” page under “Regulated Information”.
According to Sanofi, “Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply ourdeep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.”
Sanofi shares are listed on EURONEXT under SAN and on NASDAQ under SNY.
Contact information for media relations includes Sandrine Guendoul, Léo Le Bourhis, and Victor Rouault. Investor relations contacts include Thomas Kudsk Larsen, Alizé Kaisserian, Felix Lauscher, Keita Browne, Nathalie Pham, Tarik Elgoutni, Thibaud Châtelet, and Yun Li.
